Königshausen Eva, Sellin Lorenz
Department of Nephrology, University Hospital, Heinrich-Heine University, Moorenstrasse 5, 40225 Duesseldorf, Germany.
Biomed Res Int. 2016;2016:3765608. doi: 10.1155/2016/3765608. Epub 2016 Apr 21.
Primary focal segmental glomerulosclerosis (FSGS) is a major cause of the nephrotic syndrome and often leads to end-stage renal disease. This review focuses on circulating permeability factors in primary FSGS that have been implicated in the pathogenesis for a long time, partly due to the potential recurrence in renal allografts within hours after transplantation. Recently, three molecules have been proposed as a potential permeability factor by different groups: the soluble urokinase plasminogen activator receptor (suPAR), cardiotrophin-like cytokine factor-1 (CLCF-1), and CD40 antibodies. Both CLCF-1 and CD40 antibodies have not been validated by independent research groups yet. Since the identification of suPAR, different studies have questioned the validity of suPAR as a biomarker to distinguish primary FSGS from other proteinuric kidney diseases as well as suPAR's pathogenic role in podocyte damage. Researchers have suggested that cleaved molecules of suPAR have a pathogenic role in FSGS but further studies are needed to determine this role. In future studies, proposed standards for the research of the permeability factor should be carefully followed. The identification of the permeability factor in primary FSGS would be of great clinical relevance as it could influence potential individual treatment regimen.
原发性局灶节段性肾小球硬化(FSGS)是肾病综合征的主要病因,常导致终末期肾病。本综述聚焦于原发性FSGS中的循环通透性因子,长期以来它们被认为与发病机制有关,部分原因是肾移植后数小时内同种异体肾移植中可能出现复发。最近,不同研究团队提出了三种分子作为潜在的通透性因子:可溶性尿激酶型纤溶酶原激活物受体(suPAR)、心肌营养素样细胞因子-1(CLCF-1)和CD40抗体。CLCF-1和CD40抗体尚未得到独立研究团队的验证。自suPAR被发现以来,不同研究对suPAR作为区分原发性FSGS与其他蛋白尿性肾病的生物标志物的有效性以及suPAR在足细胞损伤中的致病作用提出了质疑。研究人员认为,suPAR的裂解分子在FSGS中具有致病作用,但需要进一步研究来确定这一作用。在未来的研究中,应严格遵循所提出的通透性因子研究标准。确定原发性FSGS中的通透性因子具有重要的临床意义,因为它可能影响潜在的个体化治疗方案。